Strontium ranelate related Stevens-Johnson syndrome: A case report

Osteoporosis International

Volumn 25, Issue 6, 2014, Pages 1813-1816

  Yang, C Y ^a   Chen, C H ^a   Wang, H Y ^a   Hsiao, H L ^a   Hsiao, Y H ^b   Chung, W H ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Osteoporosis; Severe cutaneous adverse reaction; Stevens Johnson syndrome; Strontium ranelate

Indexed keywords

ALPRAZOLAM; CREATININE; METHYLPREDNISOLONE; SELEGILINE; STRONTIUM RANELATE; TRIHEXYPHENIDYL; BONE DENSITY CONSERVATION AGENT; THIOPHENE DERIVATIVE;

AGED; APOPTOSIS; ARTICLE; BEDTIME DOSAGE; CASE REPORT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; KERATINOCYTE; LYMPHOCYTIC INFILTRATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; SKIN PRURITUS; STEVENS JOHNSON SYNDROME; SYSTEMIC THERAPY; DRUG ERUPTIONS; OSTEOPOROSIS, POSTMENOPAUSAL; STEVENS-JOHNSON SYNDROME;

AGED; BONE DENSITY CONSERVATION AGENTS; DRUG ERUPTIONS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; STEVENS-JOHNSON SYNDROME; THIOPHENES;

EID: 84901834860     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2688-3     Document Type: Article

References (19)

1. Fedele S, Porter SR, D'Aiuto F, Aljohani S, Vescovi P, Manfredi M, Arduino PG, Broccoletti R, Musciotto A, Di Fede O, Lazarovici TS, Campisi G, Yarom N (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123(11):1060-1064. doi: 10.1016/j.amjmed.2010. 04.033
2. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816-2822. doi: 10.1210/jc.2004-1774
3. EMEA recommends changes in the product information for Protelos/Osseor due to the risk of severe hypersensitivity reactions. Press Release (2007). http://www.emea.europa.eu/docs/en-GB/document-library/Press-release/2009/11/ WC500015592.pdf. Accessed on 28 Jun 2013.
4. Audran M, Jakob FJ, Palacios S, Brandi ML, Broll H, Hamdy NA, McCloskey EV (2013) A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatol Int. doi: 10.1007/s00296-012-2594-y
5. Liu JM, Wai-Chee Kung A, Pheng CS, Zhu HM, Zhang ZL, Wu YY, Xu L, Meng XW, Huang ML, Chung LP, Hussain NH, Sufian SS, Chen JL (2009) Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis. Bone 45(3):460-465. doi: 10.1016/j.bone.2009.05.014
6. NICE guidance: Osteoporosis - secondary prevention including strontium ranelate. www.nice.org.uk/TA161 Accessed on 21 Jun 2013
7. Lee HY, Lie D, Lim KS, Thirumoorthy T, Pang SM (2009) Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis. Osteoporos Int 20(1):161-162. doi: 10.1007/s00198-008-0677-0
8. Tan KW, Wang YS, Tay YK (2011) Stevens-Johnson syndrome due to strontium ranelate. Ann Acad Med Singap 40(11):510-511
9. Mockenhaupt M (2011) The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 7(6):803-813. doi: 10.1586/eci.11.66, quiz 814-805
10. Chung WH, Hung SI (2012) Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. J Dermatol Sci 66(3):190-196. doi: 10.1016/j.jdermsci.2012.04.002
11. Lin MS, Dai YS, Pwu RF, Chen YH, Chang NC (2005) Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J 35(3):188-190. doi: 10.1111/j.1445-5994.2005.00790.x
12. Profaizer T, Eckels D (2012) HLA alleles and drug hypersensitivity reactions. Int J Immunogenet 39(2):99-105. doi: 10.1111/j.1744-313X.2011.01061.x
13. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 102(11):4134-4139. doi: 10.1073/pnas.0409500102
14. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, Tai CT, Wu SL, Lu CH, Hsu YC, Yu HY, Ro LS, Lu CT, Chu CC, Tsai JJ, Su YH, Lan SH, Sung SF, Lin SY, Chuang HP, Huang LC, Chen YJ, Tsai PJ, Liao HT, Lin YH, Chen CH, Chung WH, Hung SI, Wu JY, Chang CF, Chen L, Chen YT, Shen CY (2011) Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 364(12):1126-1133. doi: 10.1056/NEJMoa1009717
15. Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS (2005) Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 94(4):419-436. doi: 10.1016/s1081- 1206(10)61112-x, quiz 436-418, 456
16. Aires DJ, Fraga G, Korentager R, Richie CP, Aggarwal S, Wick J, Liu DY (2013) Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality. J Drugs Dermatol JDD 12(6):679-684
17. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M (2008) Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 58(1):33-40. doi: 10.1016/j.jaad.2007.08.039
18. Haber J, Hopman W, Gomez M, Cartotto R (2005) Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil 26(1):33-41
19. Cacoub P, Descamps V, Meyer O, Speirs C, Belissa-Mathiot P, Musette P (2013) Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate. Osteoporos Int 24(5):1751-1757. doi: 10.1007/s00198-013-2265-1